RedHill Biopharma Ltd (RDHL)

[mybikeisorange]

I thought that was what you were referring to. That's not what was said. Dror said they didn't have plans to raise capital prior to RHB-104 topline data. Maybe they will do a raise at some point, but they did not "announce" that they would. Very big difference:

Dror Ben-Asher, RedHill’s CEO, said: “There is tremendous energy and enthusiasm within RedHill currently as we approach two planned Phase III readouts, with RHB-104 for Crohn’s disease in approximately three months and with TALICIA® for H. pylori infection in the fourth quarter. We are attentive to our shareholders and do not have plans to raise additional capital ahead of the MAP US Phase III study top-line results with RHB-104 for Crohn’s disease. Rapid quarter-on-quarter revenue growth from our commercial activities in the U.S. and decreased operational costs in the first quarter of 2018 underscore our continued commitment to reducing cash burn rate and building shareholder value.”